The effect of FcγRIIIA gene polymorphism on the treatment of diffuse large B-cell non-hodgkin lymphoma: A multicenter prospective observational study; [FcgRIIIA gen polimorfizminin diffüz büyük b hücreli non-hodgkin lenfoma tedavisine etkisi: Çok merkezli prospektif gözlemsel Çalışma]

Simple item page
dc.contributor.authorBüyükkurt N.
dc.contributor.authorÖzcan M.A.
dc.contributor.authorErgene Ü.
dc.contributor.authorPayzın B.
dc.contributor.authorTunalı S.
dc.contributor.authorDemirkan F.
dc.contributor.authorÖzsan H.
dc.contributor.authorPişkin Ö.
dc.contributor.authorÜndar B.
dc.date.accessioned2024-07-22T08:14:15Z
dc.date.available2024-07-22T08:14:15Z
dc.date.issued2015
dc.description.abstractObjective: The curative treatment approach for diffuse large B-cell lymphoma (DLBCL) is controversial even in the rituximab (R) era. The aim of this study was to examine the FcgRIIIA gene polymorphism distribution of DLBCL patients who had been treated with R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. Furthermore, we investigated the impact of FcgRIIIA gene polymorphism on the overall response rate (ORR) and overall survival (OS). Materials and Methods: Patients from 3 centers in the Aegean region of Turkey who had newly diagnosed CD20-positive DLBCL were enrolled in the study. The single nucleotide polymorphisms of the FcgRIIIA gene were analyzed by real time- PCR. The response to treatment was determined in the middle and at the end of the protocol. During 2 years of follow-up, the patients were clinically and radiologically evaluated for disease status every 3 months. Results: Thirty-six patients were included in the study and the distributions of F/F, V/F, and V/V types of alleles of FcgRIIIA were 25%, 50%, and 25%, respectively. Twenty-seven patients were considered as evaluable according to ORR and OS. The patients’ oRR was 87.5%, 100%, and 50% in the F/F, V/F, and V/V allele groups, respectively. We did not establish any statistically significant differences among the 3 alleles groups in respect to ORR (p=0.93). The OS within 2 years in the F/F, V/F, and V/V allele groups was 62.5%, 100%, and 100%, respectively. The OS in the F/F allele group was found to be lower than in the other 2 allele groups (p=0.01). Conclusion: The distribution of gene polymorphisms in our study group was similar to those of previous studies. While oRR was similar between the groups, our results highlight a lower OS in F/F patients compared to other allele groups of FcgRIIIA. © 2015, Turkish Society of Hematology. All rights reserved.
dc.identifier.DOI-ID10.4274/tjh.2013.0367
dc.identifier.issn13007777
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/16528
dc.language.isoEnglish
dc.publisherTurkish Society of Hematology
dc.rightsAll Open Access; Gold Open Access
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAlleles
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectCyclophosphamide
dc.subjectDoxorubicin
dc.subjectFemale
dc.subjectFollow-Up Studies
dc.subjectGene Frequency
dc.subjectGenotype
dc.subjectHumans
dc.subjectLymphoma, Large B-Cell, Diffuse
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPolymorphism, Single Nucleotide
dc.subjectPrednisone
dc.subjectProspective Studies
dc.subjectReal-Time Polymerase Chain Reaction
dc.subjectReceptors, IgG
dc.subjectRituximab
dc.subjectSeverity of Illness Index
dc.subjectSurvival Rate
dc.subjectTreatment Outcome
dc.subjectTurkey
dc.subjectVincristine
dc.subjectYoung Adult
dc.subjectCD20 antigen
dc.subjectcyclophosphamide
dc.subjectdoxorubicin
dc.subjectFc receptor IIa
dc.subjectprednisone
dc.subjectrituximab
dc.subjectvincristine
dc.subjectantineoplastic agent
dc.subjectcyclophosphamide
dc.subjectdoxorubicin
dc.subjectFc receptor
dc.subjectFCGR3A protein, human
dc.subjectprednisone
dc.subjectrituximab
dc.subjectvincristine
dc.subjectadult
dc.subjectaged
dc.subjectallele
dc.subjectArticle
dc.subjectclinical article
dc.subjectDNA polymorphism
dc.subjectFc receptor IIa gene
dc.subjectfemale
dc.subjectfollow up
dc.subjectgene
dc.subjecthuman
dc.subjectlarge cell lymphoma
dc.subjectmale
dc.subjectmulticenter study
dc.subjectoverall survival
dc.subjectradiotherapy
dc.subjectreal time polymerase chain reaction
dc.subjectsingle nucleotide polymorphism
dc.subjecttreatment response
dc.subjectclinical trial
dc.subjectepidemiology
dc.subjectgene frequency
dc.subjectgenetics
dc.subjectgenotype
dc.subjectLymphoma, Large B-Cell, Diffuse
dc.subjectmiddle aged
dc.subjectprospective study
dc.subjectseverity of illness index
dc.subjectsingle nucleotide polymorphism
dc.subjectsurvival rate
dc.subjecttreatment outcome
dc.subjectTurkey
dc.subjectvery elderly
dc.subjectyoung adult
dc.titleThe effect of FcγRIIIA gene polymorphism on the treatment of diffuse large B-cell non-hodgkin lymphoma: A multicenter prospective observational study; [FcgRIIIA gen polimorfizminin diffüz büyük b hücreli non-hodgkin lenfoma tedavisine etkisi: Çok merkezli prospektif gözlemsel Çalışma]
dc.typeArticle

Files

Collections

Scopus Koleksiyonu